Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136268 | 0.99 | HPGDS (0.53) | HPGDSHRH3USP30EGLN1KMT2A | |
| SCHEMBL4143603 | 0.98 | HPGDS (0.53) | HPGDSHRH3USP30EGLN1KMT2A | |
| SCHEMBL4125572 | 0.98 | HPGDS (0.53) | HPGDSHRH3USP30EGLN1KMT2A | |
| SCHEMBL4130565 | 0.88 | HRH3 (0.52) | HRH3ADRA1AHDAC1 | |
| SCHEMBL4137012 | 0.86 | HRH3 (0.55) | HRH3ADRA1AHDAC1 | |
| SCHEMBL4130249 | 0.85 | ALDH1A1 (0.50) | HPGDSHRH3ADRA1AHDAC1 | |
| SCHEMBL4130587 | 0.85 | HRH3 (0.51) | HRH3ADRA1A | |
| SCHEMBL4139822 | 0.85 | HRH3 (0.48) | HPGDSHRH3ADRA1AHDAC1 | |
| SCHEMBL4137203 | 0.84 | SMN1; SMN2 (0.52) | HPGDSHRH3EGLN1ADRA1AHDAC1 | |
| SCHEMBL4936546 | 0.84 | HRH3 (0.64) | HRH3KMT2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | HPGDS 397/4885HRH3 1/4885USP30 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.